Literature DB >> 22668624

Salivary adenocarcinoma, not otherwise specified: a clinicopathological study of 28 cases.

Runzhi Deng1, Enyi Tang, Xudong Yang, Xiaofeng Huang, Qingang Hu.   

Abstract

OBJECTIVE: The objective of this study was to summarize the clinicopathologic features of salivary adenocarcinoma, not otherwise specified (ANOS) and to evaluate current treatments. STUDY
DESIGN: Between 1992 and 2010, 28 patients with ANOS were diagnosed and treated. Clinical data of demographic features, resection margin, neck dissection status, recurrence, and mortality were reviewed.
RESULTS: The parotid had the most frequent incidence of ANOS and the palate was second. The peak onset was between 40 and 60 years. The preferred management modality was surgical intervention in all cases. Neck dissection and postoperative radiotherapy were performed in 67.9% and 64.3%, respectively. The mean survival time was 97 months. The 5- and 10-year overall survival rates were 62.2% and 36.0%, respectively.
CONCLUSIONS: The current data demonstrate that T, N, M, and Union for International Cancer Control staging, resection margin, and neck dissection status are the most powerful predictors of survival. Long-term follow-up is required to identify possible late recurrence.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22668624     DOI: 10.1016/j.oooo.2011.11.019

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  7 in total

1.  Intraoral Pigmented Low-Grade Adenocarcinoma, Not Otherwise Specified: Case Report and Immunohistochemical Study.

Authors:  Jessica Luana Dos Santos; Albina Messias de Almeida Milani Altemani; Alexandre Elias Trivellato; Cássio Edvard Sverzut; Luciana Yamamoto Almeida; Lucas Ribeiro Teixeira; Alfredo Ribeiro-Silva; Jorge Esquiche León
Journal:  Head Neck Pathol       Date:  2017-12-22

2.  Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Authors:  Claudia Scherl; Marlen Haderlein; Abbas Agaimy; Konstantinos Mantsopoulos; Michael Koch; Maximilian Traxdorf; Rainer Fietkau; Philipp Grundtner; Heinrich Iro
Journal:  Strahlenther Onkol       Date:  2019-07-26       Impact factor: 3.621

3.  Carcinoma Ex Pleomorphic Adenoma Presented as a Gigantic Tumor: Treatment and Diagnostic Challenges.

Authors:  Thevagi Maruthamuthu; Jeyasakthy Saniasiaya; Irfan Mohamad; Sanjeevan Nadarajah; Norhafiza Mat Lazim; Wan Faiziah Wan Abdul Rahman
Journal:  Oman Med J       Date:  2018-07

4.  Establishment and Validation of Prognostic Nomograms for Patients With Parotid Gland Adenocarcinoma Not Otherwise Specified: A SEER Analysis From 2004 to 2016.

Authors:  Zi-Meng Wang; Zuo-Lin Xiang
Journal:  Front Surg       Date:  2022-01-11

5.  Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period.

Authors:  Michał Żurek; Kamil Jasak; Karolina Jaros; Piotr Daniel; Kazimierz Niemczyk; Anna Rzepakowska
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

Review 6.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

7.  Tumor to Tumor Metastasis from Adenocarcinoma Not Otherwise Specified of the Parotid Gland to Uterine Leiomyoma: Presentation of a Unique Case.

Authors:  Alexandros Psarris; Nektarios Koufopoulos; Anastasios Grivas; Dimitrios C Papatheodorou; Lubna Khaldi
Journal:  Cureus       Date:  2020-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.